Abbott’s Sundareswaran envisions TEAM-HF & earlier interventions to redefine heart failure outcomes
In this episode of AbbottTalks, Kartik Sundareswaran, PhD, divisional VP, global clinical and regulatory affairs, Abbott Heart Failure, discusses Abbott’s pioneering work in heart failure care, focusing on technologies that improve outcomes and empower earlier interventions.
Sundareswaran’s path to MedTech began with a shift from computer engineering to biomedical research, where his early work studying blood flow patterns in children with congenital heart disease sparked a passion for solving cardiovascular challenges. This passion led him to roles at Thoratec, St. Jude Medical, and ultimately Abbott, where he has spent years advancing heart failure care.
The conversation highlights Abbott’s CardioMEMS™ Heart Failure System, a device enabling remote pulmonary artery pressure monitoring to reduce hospitalizations, and the HeartMate 3 LVAD, which provides life-extending support for patients with advanced heart failure. Sundareswaran also discusses the new TEAM-HF clinical trial, which combines CardioMEMS and HeartMate 3 to identify patients earlier and deliver timely, effective interventions.
This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about how Tecan works with medical device companies, visit: https://partnering.tecan.com/
Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.
Sundareswaran’s path to MedTech began with a shift from computer engineering to biomedical research, where his early work studying blood flow patterns in children with congenital heart disease sparked a passion for solving cardiovascular challenges. This passion led him to roles at Thoratec, St. Jude Medical, and ultimately Abbott, where he has spent years advancing heart failure care.
The conversation highlights Abbott’s CardioMEMS™ Heart Failure System, a device enabling remote pulmonary artery pressure monitoring to reduce hospitalizations, and the HeartMate 3 LVAD, which provides life-extending support for patients with advanced heart failure. Sundareswaran also discusses the new TEAM-HF clinical trial, which combines CardioMEMS and HeartMate 3 to identify patients earlier and deliver timely, effective interventions.
This conversation comes to you courtesy of our episode sponsor, Tecan Group Ltd. To learn more about how Tecan works with medical device companies, visit: https://partnering.tecan.com/
Thank you for listening to the AbbottTalks Podcast. Tune in and subscribe to DeviceTalks on all major podcast channels to never miss an episode.
Activity